Endocrine Abstracts

Background: Immune checkpoint inhibitors (ICIs) showed impressive results in several malignancies; however, a large spectrum of immune-related adverse events (IRAEs) may occur, including thyroid dysfunction (DYSTHYR). IRAEs seem to be associated with better cancer outcome; limited data suggested that thyroid toxicity could be a predictor of response to ICIs.Patients and methods: We retrospectively evaluated all patients who started treatment with the pro...